Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, is the brand facing a decline?
Welcome to OmegaTown, also known as Newport, Rhode Island. This summer, RB set up camp in the seaside fishing community to put omega-3s to the test.
Novo Nordisk is hooking up with new-wave weight loss program Noom to support people with obesity.
Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.
Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.
Is AbbVie duplicating its Humira TV strategy with follow-up Skyrizi? With the first Skyrizi campaign, the Illinois company jumped quickly into TV ads.
AbbVie's contribution to patient assistance groups and other nonprofits skyrocketed to about $350 million in 2018, from below $100 million in 2015.
GlaxoSmithKline’s first campaign for new two-in-one HIV pill Dovato centers on real patients who want to be seen for who they are, not as a diagnosis.
After two years of turmoil, Outcome Health is done with its apology tour and ready to debut its change-agent strategy.
